



CORVENTIS LAUNCHES AND ANNOUNCES AVAILABILITY OF THE AVIVO™ MOBILE PATIENT MANAGEMENT SYSTEM

Company's Wireless Cardiovascular Solutions Designed to Improve Management of Heart Conditions

San Jose, Calif. – April 21, 2009 – Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, launched officially today and announced availability of its non-invasive, wireless system to monitor cardiac health. Corventis' inaugural product, the AVIVO™ Mobile Patient Management System, has received U.S. Food and Drug Administration (FDA) clearance and is now commercially available for use by clinicians within and outside the United States.

The company's platform technology is designed to deliver focused visibility into the cardiac health status of patients by combining patient-friendly wearable sensors with advanced computational algorithms, global wireless capabilities and a comprehensive web-based infrastructure.

The system provides clinicians actionable information on an exception basis to help diagnose potential health risks, including non-lethal arrhythmias, from anywhere across the globe.

"The Corventis platform offers a range of information about the patient's health status that has been, until now, possible only through the implantation of a device – an invasive procedure," said Eric J. Topol, M.D., director of the Scripps Translational Science Institute and chief academic officer of Scripps Health, who demonstrated the technology live earlier this month in a keynote address at the CTIA – The Wireless Association® conference in Las Vegas. "This is an example of how non-invasive wireless technology has the potential to markedly transform the way we monitor patients on a continuous and remote basis."

"The Corventis technology platform has the potential to transform arrhythmia monitoring for both patients at home and eventually, hospitalized patients," said Leslie Saxon, M.D., chief, division of cardiology, Keck School of Medicine at the University of Southern California, Los Angeles, who is the founder of the annual Body Computing Conference and a pioneer in the field of networked medical devices. "The freedom of movement and timely arrhythmia detection will create a comfortable environment for all patients. We've learned that networked devices that can provide nearly instantaneous diagnosis, treatment and reassurance to patients answer one of the greatest needs in medicine today."

Cardiac arrhythmias can cause chest pain and fainting, and some lethal arrhythmias can lead to sudden cardiac death. More than two million Americans have atrial fibrillation, a type of cardiac arrhythmia that is associated with an increased risk for stroke. 835,000 Americans are discharged from hospital care with cardiac arrhythmia diagnoses each year.

"Our mission is to advance healthcare through the confluence of advanced sensor microelectronics, wireless and internet technologies, providing physicians unprecedented visibility into a patient's health status and enabling individualized preventive care," said Ed Manicka, Ph.D., president and CEO of Corventis. "We are very proud of our accomplishments to date, including filing more than 50 patents internationally, deploying our solutions around the globe, successful enrollments in our clinical program and receiving this FDA clearance for our technology. The elegant solution we have developed will serve as a platform for multiple future products designed to improve the way heart conditions are managed."



“The range of physiological information made available and the ease with which that information is collected and reviewed is one of the most exciting aspects of the Corventis platform,” said Inder Anand, M.D., Ph.D., director of the Heart Failure Program, Minneapolis, VA Medical Center and Professor of Medicine, University of Minnesota, Minn. “By carefully evaluating changes in physiological status identified with a Corventis solution, cardiologists may soon have a tool to proactively manage heart failure patients and reduce re-hospitalizations.”

According to the American Heart Association, more than five million Americans are living with heart failure, and each year more than one million patients are hospitalized with the condition. Up to 50 percent are readmitted within six months of discharge.

About Corventis Technology

Corventis develops wireless cardiovascular solutions that promise to improve clinical outcomes and reduce healthcare costs.

Electrocardiograms (ECG) and other tests performed in a hospital or clinic setting provide valuable information about the rhythm of the heart and overall patient health status. In many cases, however, it is necessary to monitor heart rhythm or other physiological signals for a longer period of time for a better understanding of the patient’s condition.

The company’s elegant PiiX™ wearable sensor enables continuous monitoring for ambulatory patients – providing clinicians with insight into patient cardiovascular health during normal daily routines. The PiiX sensor automatically collects physiological information and wirelessly transmits the data from the patient to Corventis for further analysis and presentation on a secure website.

With no cumbersome leads and wires, the patient-friendly design of PiiX encourages continuous wear, even while showering or sleeping. Fully automated collection and transmission of data also minimizes the number of steps required by the patient to ensure reliable event detection.

For physicians, Corventis wireless technology offers ongoing visibility into a patient’s cardiac health status previously accessible with invasive implantable devices. Multiple sensors on the PiiX enable intelligent detection of clinical events and the creation of comprehensive heart rate, respiratory rate, fluid status, posture and activity trends. Clinical event information such as ECG is captured on an exception basis, enabling focused review and diagnosis by clinicians.

About Corventis

Corventis, Inc. is a pioneer in wireless cardiovascular solutions. The company’s technology enables global personalized patient care by providing clinicians with actionable diagnoses for early detection, prevention and treatment. Corventis is funded by prominent venture capital firms Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures and DAG Ventures. Privately held, the company is located in San Jose, Calif. For more information visit www.corventis.com.

###